

Sven Perner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2609786/publications.pdf>

Version: 2024-02-01

150
papers

21,338
citations

24978

57
h-index

9553

142
g-index

152
all docs

152
docs citations

152
times ranked

26775
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer. <i>American Journal of Pathology</i> , 2022, 192, 813-823.	1.9	4
2	Targeting cyclin-dependent kinase 7 association between CDK7 and pMED1 expression in prostate cancer tissue. <i>Carcinogenesis</i> , 2022, 43, 779-786.	1.3	4
3	Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 380.e11-380.e18.	0.8	1
4	TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC. <i>Journal of Personalized Medicine</i> , 2022, 12, 991.	1.1	6
5	Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 229-250.	2.3	27
6	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , 2021, 79, 519-529.	0.9	30
7	Novel approaches to target the microenvironment of bone metastasis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 488-505.	12.5	91
8	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. <i>Carcinogenesis</i> , 2021, 42, 1475-1484.	1.3	5
9	CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. <i>Human Pathology</i> , 2021, 117, 60-67.	1.1	3
10	Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 632-644.	3.2	49
11	Chromothripsis followed by circular recombination drives oncogene amplification in human cancer. <i>Nature Genetics</i> , 2021, 53, 1673-1685.	9.4	61
12	The new ISUP 2014/WHO 2016 prostate cancer grade group system: first results 5 years after introduction and systemic review of the literature. <i>World Journal of Urology</i> , 2020, 38, 657-662.	1.2	12
13	Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 261-271.	1.4	15
14	Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. <i>International Journal of Cancer</i> , 2020, 146, 577-588.	2.3	23
15	Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 561-568.	1.4	21
16	GC1qR Cleavage by Caspase-1 Drives Aerobic Glycolysis in Tumor Cells. <i>Frontiers in Oncology</i> , 2020, 10, 575854.	1.3	15
17	Lung cancer biomarker testing: perspective from Europe. <i>Translational Lung Cancer Research</i> , 2020, 9, 887-897.	1.3	25
18	CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5508.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 636.e7-636.e12.	0.8	7
20	A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). <i>Radiotherapy and Oncology</i> , 2019, 139, 79-82.	0.3	25
21	TRIM24 as an independent prognostic biomarker for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 576.e1-576.e10.	0.8	18
22	KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. <i>Nature Structural and Molecular Biology</i> , 2019, 26, 361-371.	3.6	57
23	Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 27.	1.2	54
24	<i>In silico</i> analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2493-2496.	0.6	0
25	DNA methylation-based reclassification of olfactory neuroblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 255-271.	3.9	59
26	Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma. <i>American Journal of Pathology</i> , 2018, 188, 72-83.	1.9	22
27	Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. <i>Frontiers in Oncology</i> , 2018, 8, 623.	1.3	108
28	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	6.0	213
29	Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissues. <i>International Journal of Cancer</i> , 2018, 143, 3061-3070.	2.3	8
30	Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. <i>Cancer Research</i> , 2017, 77, 2148-2160.	0.4	36
31	Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy. <i>Oncology Letters</i> , 2017, 13, 22-28.	0.8	15
32	ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 3040-3056.	0.4	81
33	Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 1643-1653.	2.3	21
34	Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1829-1840.	3.2	74
35	Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 7.	1.8	36
36	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. <i>Frontiers in Medicine</i> , 2017, 4, 30.	1.2	13

#	ARTICLE	IF	CITATIONS
37	Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups. <i>Frontiers in Medicine</i> , 2017, 4, 157.	1.2	21
38	IL-4/5 signalling plays an important role during <i>Litomosoides sigmodontis</i> infection, influencing both immune system regulation and tissue pathology in the thoracic cavity. <i>International Journal for Parasitology</i> , 2017, 47, 951-960.	1.3	16
39	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. <i>Oncotarget</i> , 2017, 8, 7964-7976.	0.8	16
40	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 14719-14735.	0.8	21
41	IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. <i>American Journal of Pathology</i> , 2016, 186, 974-984.	1.9	17
42	Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. <i>Targeted Oncology</i> , 2016, 11, 631-642.	1.7	10
43	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <i>Oncolmmunology</i> , 2016, 5, e1131379.	2.1	94
44	<scp>NOTCH</scp>, <scp>ASCL1</scp>, p53 and <scp>RB</scp> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. <i>International Journal of Cancer</i> , 2016, 138, 927-938.	2.3	143
45	<i>Ercc1</i> Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a <i>Tp53</i> Context-Specific Manner. <i>Molecular Cancer Research</i> , 2016, 14, 1110-1123.	1.5	18
46	Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. <i>International Journal of Cancer</i> , 2016, 139, 2359-2369.	2.3	27
47	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic<i>TMPRSS2:ERG</i>fusion status. <i>Human Molecular Genetics</i> , 2016, 25, ddw349.	1.4	8
48	Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. <i>BMC Bioinformatics</i> , 2016, 17, 72.	1.2	140
49	Exome sequencing identifies potential novel candidate genes in patients with unexplained colorectal adenomatous polyposis. <i>Familial Cancer</i> , 2016, 15, 281-288.	0.9	40
50	Low-level<i>APC</i>mutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. <i>Journal of Medical Genetics</i> , 2016, 53, 172-179.	1.5	51
51	Assembly of methylated KDM1A and CHD1 drives androgen receptorâ€‘dependent transcription and translocation. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 132-139.	3.6	70
52	The activation of OR51E1 causes growth suppression of human prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 48231-48249.	0.8	53
53	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. <i>Oncotarget</i> , 2016, 7, 23043-23055.	0.8	24
54	MERTK as a novel therapeutic target in head and neck cancer. <i>Oncotarget</i> , 2016, 7, 32678-32694.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. <i>Translational Oncology</i> , 2015, 8, 487-496.	1.7	9
56	AIM2 Drives Joint Inflammation in a Self-DNA Triggered Model of Chronic Polyarthritis. <i>PLoS ONE</i> , 2015, 10, e0131702.	1.1	85
57	FGFR1 Expression Levels Predict BGI398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 4356-4364.	3.2	75
58	Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer. <i>Pathology</i> , 2015, 47, 629-636.	0.3	22
59	Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. <i>Modern Pathology</i> , 2015, 28, 138-145.	2.9	45
60	Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 415-422.	1.2	66
61	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015, 524, 47-53.	13.7	1,634
62	Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. <i>Genomics Data</i> , 2015, 5, 173-175.	1.3	32
63	Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. <i>Scandinavian Journal of Urology</i> , 2015, 49, 382-387.	0.6	11
64	Clinical and Molecular Implications of MED15 in Head and Neck Squamous Cell Carcinoma. <i>American Journal of Pathology</i> , 2015, 185, 1114-1122.	1.9	21
65	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	13.7	478
66	Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 35542-35555.	0.8	60
67	Molecular and functional interactions between AKT and SOX2 in breast carcinoma. <i>Oncotarget</i> , 2015, 6, 43540-43556.	0.8	37
68	Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma. <i>PLoS ONE</i> , 2014, 9, e86194.	1.1	42
69	Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma. <i>Molecular Cancer Research</i> , 2014, 12, 1460-1469.	1.5	38
70	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. <i>Clinical Cancer Research</i> , 2014, 20, 3299-3309.	3.2	141
71	Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. <i>Nature Medicine</i> , 2014, 20, 1401-1409.	15.2	50
72	Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (<scp>RCC</scp>). <i>BJU International</i> , 2014, 113, 209-217.	1.3	26

#	ARTICLE	IF	CITATIONS
73	<i>MED15</i> , encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2014, 135, 19-26.	2.3	24
74	GNAS Sequencing Identifies IPMN-specific Mutations in a Subgroup of Diminutive Pancreatic Cysts Referred to as "Incipient IPMNs". <i>American Journal of Surgical Pathology</i> , 2014, 38, 360-363.	2.1	52
75	Single-Cell Genetic Analysis Reveals Insights into Clonal Development of Prostate Cancers and Indicates Loss of PTEN as a Marker of Poor Prognosis. <i>American Journal of Pathology</i> , 2014, 184, 2671-2686.	1.9	29
76	Prognostic significance of phospho-histone H3 in prostate carcinoma. <i>World Journal of Urology</i> , 2014, 32, 703-707.	1.2	28
77	KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. <i>American Journal of Pathology</i> , 2014, 184, 2430-2437.	1.9	69
78	Prevention and early detection of prostate cancer. <i>Lancet Oncology</i> , The, 2014, 15, e484-e492.	5.1	372
79	Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2014, 35, 1636-1642.	1.3	66
80	<i>CD74</i> - <i>NRG1</i> Fusions in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2014, 4, 415-422.	7.7	238
81	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. <i>Nature Medicine</i> , 2014, 20, 1027-1034.	15.2	243
82	Landscape of chromosome number changes in prostate cancer progression. <i>World Journal of Urology</i> , 2013, 31, 1489-1495.	1.2	14
83	<i>SOX2</i> Expression Associates with Stem Cell State in Human Ovarian Carcinoma. <i>Cancer Research</i> , 2013, 73, 5544-5555.	0.4	129
84	Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal Treatment-Related Neuroendocrine Prostate Cancer. <i>Neoplasia</i> , 2013, 15, 1-IN4.	2.3	205
85	Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer Patients Following Radical Prostatectomy. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 270-279.	1.2	53
86	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3</i> - <i>ERG</i> gene rearrangement and an unfavorable clinical course. <i>International Journal of Cancer</i> , 2013, 132, 807-812.	2.3	39
87	Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. <i>Modern Pathology</i> , 2013, 26, 1298-1306.	2.9	54
88	Activation of Invariant NK T Cells in Periodontitis Lesions. <i>Journal of Immunology</i> , 2013, 190, 2282-2291.	0.4	30
89	SOX2 Expression and Prognostic Significance in Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 358-367.	0.9	37
90	Role of the NK Cell-Activating Receptor CRACC in Periodontitis. <i>Infection and Immunity</i> , 2013, 81, 690-696.	1.0	32

#	ARTICLE	IF	CITATIONS
91	Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer. <i>Digestion</i> , 2013, 88, 172-181.	1.2	25
92	Comparison of p40 (p63) and p63 expression in prostate tissues – which one is the superior diagnostic marker for basal cells?. <i>Histopathology</i> , 2013, 63, 50-56.	1.6	22
93	Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. <i>Histopathology</i> , 2013, 63, 157-166.	1.6	41
94	Sex Determining Region Y-Box 2 (SOX2) Amplification Is an Independent Indicator of Disease Recurrence in Sinonasal Cancer. <i>PLoS ONE</i> , 2013, 8, e59201.	1.1	32
95	Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. <i>Histology and Histopathology</i> , 2013, 28, 605-10.	0.5	52
96	The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key?. <i>Molecular Medicine Reports</i> , 2012, 5, 313-6.	1.1	41
97	Exome Enrichment and SOLiD Sequencing of Formalin Fixed Paraffin Embedded (FFPE) Prostate Cancer Tissue. <i>International Journal of Molecular Sciences</i> , 2012, 13, 8933-8942.	1.8	28
98	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. <i>Modern Pathology</i> , 2012, 25, 1473-1480.	2.9	118
99	Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using Fibroblast Growth Factor Receptor Inhibitors. <i>Chest</i> , 2012, 142, 1020-1026.	0.4	47
100	ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 157-162.	1.4	11
101	Differences in Frequency of ERG Oncoprotein Expression Between Index Tumors of Caucasian and African American Patients With Prostate Cancer. <i>Urology</i> , 2012, 80, 749-753.	0.5	73
102	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	9.4	1,186
103	Methylglutathione S-transferase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. <i>Prostate</i> , 2012, 72, 301-306.	1.2	9
104	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. <i>Cancer Discovery</i> , 2011, 1, 487-495.	7.7	725
105	Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. <i>Histopathology</i> , 2011, 58, 1028-1036.	1.6	33
106	Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. <i>World Journal of Urology</i> , 2011, 29, 451-456.	1.2	37
107	Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 129-137.	2.1	60
108	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2391-2396.	0.8	140

#	ARTICLE	IF	CITATIONS
109	SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. <i>Modern Pathology</i> , 2011, 24, 944-953.	2.9	177
110	Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. <i>Prostate</i> , 2010, 70, 491-501.	1.2	130
111	<i>ERG</i> rearrangement in small cell prostatic and lung cancer. <i>Histopathology</i> , 2010, 56, 937-943.	1.6	64
112	An Oncogenic Role for <i>ETV1</i> in Melanoma. <i>Cancer Research</i> , 2010, 70, 2075-2084.	0.4	107
113	Frequent and Focal <i>FGFR1</i> Amplification Associates with Therapeutically Tractable <i>FGFR1</i> Dependency in Squamous Cell Lung Cancer. <i>Science Translational Medicine</i> , 2010, 2, 62ra93.	5.8	761
114	Prevalence of <i>TMPRSS2-ERG</i> and <i>SLC45A3-ERG</i> gene fusions in a large prostatectomy cohort. <i>Modern Pathology</i> , 2010, 23, 539-546.	2.9	141
115	<i>ERG</i> rearrangement is specific to prostate cancer and does not occur in any other common tumor. <i>Modern Pathology</i> , 2010, 23, 1061-1067.	2.9	114
116	<i>ERG</i> Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer. <i>Urology</i> , 2010, 75, 762-767.	0.5	56
117	<i>ERG</i> Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. <i>Neoplasia</i> , 2010, 12, 1031-IN22.	2.3	51
118	Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 595-600.	1.1	60
119	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2009, 8, 2042-2050.	1.5	78
120	Prevalence of <i>TMPRSS2-ERG</i> Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. <i>Clinical Cancer Research</i> , 2009, 15, 4706-4711.	3.2	205
121	In Situ Evidence of <i>KRAS</i> Amplification and Association With Increased p21 Levels in Non-Small Cell Lung Carcinoma. <i>American Journal of Clinical Pathology</i> , 2009, 132, 500-505.	0.4	24
122	Genome-Wide Linkage Analysis of <i>TMPRSS2-ERG</i> Fusion in Familial Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 640-646.	0.4	32
123	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. <i>Journal of Clinical Oncology</i> , 2009, 27, 3459-3464.	0.8	329
124	Clinical significance of <i>TTF1</i> protein expression and <i>TTF1</i> gene amplification in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1977-1986.	1.6	98
125	Retinoid metabolism and <i>ALDH1A2</i> (<i>RALDH2</i>) expression are altered in the transgenic adenocarcinoma mouse prostate model. <i>Biochemical Pharmacology</i> , 2009, 78, 1127-1138.	2.0	37
126	Distinct genomic aberrations associated with <i>ERG</i> rearranged prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 366-380.	1.5	86

#	ARTICLE	IF	CITATIONS
127	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. <i>Nature Genetics</i> , 2009, 41, 1238-1242.	9.4	862
128	Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens by a Novel Assay Using Branched DNA. <i>Urology</i> , 2009, 74, 1156-1161.	0.5	14
129	N-myc Downstream Regulated Gene 1 (NDRG1) Is Fused to ERG in Prostate Cancer. <i>Neoplasia</i> , 2009, 11, 804-W18.	2.3	105
130	An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2008, 21, 411-421.	1.1	27
131	Expression changes of CAV1 and EZH2, located on 7q31 ¹ q36, are rarely related to genomic alterations in primary prostate carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2008, 182, 103-110.	1.0	22
132	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. <i>Cancer Cell</i> , 2008, 13, 519-528.	7.7	303
133	EML4-ALK Fusion Lung Cancer: A Rare Acquired Event. <i>Neoplasia</i> , 2008, 10, 298-302.	2.3	231
134	Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1682-1688.	1.1	19
135	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 815-825.	3.0	286
136	Characterization of <i>TMPRSS2-ERG</i> Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. <i>Clinical Cancer Research</i> , 2008, 14, 3380-3385.	3.2	200
137	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20007-20012.	3.3	927
138	TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion. <i>American Journal of Surgical Pathology</i> , 2007, 31, 882-888.	2.1	394
139	TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications. <i>Urology</i> , 2007, 70, 630-633.	0.5	146
140	Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. <i>Human Pathology</i> , 2007, 38, 696-701.	1.1	388
141	Molecular Characterization of TMPRSS2-ERG Gene Fusion in the NCI-H660 Prostate Cancer Cell Line: A New Perspective for an Old Model. <i>Neoplasia</i> , 2007, 9, 200-IN3.	2.3	119
142	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007, 450, 893-898.	13.7	1,020
143	Prognostic factors in lymph node-positive prostate cancer. <i>Urology</i> , 2006, 67, 1016-1021.	0.5	41
144	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 8337-8341.	0.4	475

#	ARTICLE	IF	CITATIONS
145	Imaging prostate cancer with 11C-choline PET/CT. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1249-54.	2.8	191
146	Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. <i>Science</i> , 2005, 310, 644-648.	6.0	3,541
147	A Case of Sudden Cardiac Death Due to Isolated Eosinophilic Coronary Arteritis. <i>Chest</i> , 2005, 128, 1047-1050.	0.4	42
148	Quantifying Telomere Lengths of Human Individual Chromosome Arms by Centromere-Calibrated Fluorescence in Situ Hybridization and Digital Imaging. <i>American Journal of Pathology</i> , 2003, 163, 1751-1756.	1.9	92
149	A fatal case of necrotizing sinusitis due to toxigenic <i>Corynebacterium ulcerans</i> . <i>International Journal of Medical Microbiology</i> , 2002, 292, 59-63.	1.5	29
150	Differential and Mutually Exclusive Expression of CD95 and CD95 Ligand in Epithelia of Normal Pancreas and Chronic Pancreatitis. <i>Laboratory Investigation</i> , 2001, 81, 317-326.	1.7	17